Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative net margin of 214.70% and a negative return on equity of 59.07%.
Shares of NASDAQ ALPN opened at $7.55 on Friday. The stock’s 50-day moving average is $8.56 and its two-hundred day moving average is $10.01. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.75 and a current ratio of 2.75. Alpine Immune Sciences has a 1-year low of $6.00 and a 1-year high of $15.14.
A number of research analysts have weighed in on ALPN shares. Oppenheimer cut their price objective on shares of Alpine Immune Sciences from $19.00 to $17.00 in a research report on Monday, March 7th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Alpine Immune Sciences in a report on Friday. Finally, Zacks Investment Research lowered shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, March 22nd.
About Alpine Immune Sciences (Get Rating)
Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.
- Get a free copy of the StockNews.com research report on Alpine Immune Sciences (ALPN)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Want More Great Investing Ideas?
- 3 Stocks to DOUBLE This Year
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 9 "MUST OWN" Growth Stocks
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.